Skip to main content
Erschienen in: Drug Safety 13/2001

01.11.2001 | Leading Article

Methods and Systems to Detect Adverse Drug Reactions in Hospitals

verfasst von: Dr Petra A. Thürmann

Erschienen in: Drug Safety | Ausgabe 13/2001

Einloggen, um Zugang zu erhalten

Abstract

Detection of adverse drug reactions (ADRs) in hospitals offers the chance to detect serious ADRs resulting in hospitalisation and ADRs occurring in hospitalised patients, i.e. patients with high comorbidity and receiving drugs that are administered only in hospitals. The most commonly applied methods involve stimulated spontaneous reporting of doctors and nurses, comprehensive collection by trained specialists and, more recently, computer-assisted approaches using routine data from hospital information systems. The different methods of ADR detection used result in different rates and types of ADRs and, consequently, in different drug classes being responsible for these ADRs. Another factor influencing the results of surveys is the interpretation of the term ADR, where some authors adhere to the strict definition of the World Health Organization and many others include intended and unintended poisoning as well as errors in prescribing and dispensing, thus referring to adverse drug events. Depending on the method used for screening of patients, a high number of possible ADRs and only few definite ADRs are found, or vice versa. These variations have to be taken into account when comparing the results of further analyses performed with these data. ADR rates and incidences in relation to the number of drugs prescribed or patients exposed have been calculated in only a few surveys and projects, and this interesting pharmacoepidemiological approach deserves further study. In addition, the pharmacoeconomic impact ofADRs, either resulting in hospitalisation or prolonging hospital stay, has been estimated using different approaches. However, a common standardised procedure for such calculations has not yet been defined. Although detection of ADRs in hospitals offers the opportunity to detect severe ADRs of newly approved drugs, these ADRs are still discovered by spontaneous reporting systems. The prospects offered by electronic hospital information systems as well as implementation of pharmacoepidemiological approaches increases the possibilities and the value of ADR detection in hospitals.
Literatur
2.
Zurück zum Zitat Hurwitz N, Wade OL. Intensive hospital monitoring of adverse reactions to drugs. BMJ 1969; 1: 536–9PubMedCrossRef Hurwitz N, Wade OL. Intensive hospital monitoring of adverse reactions to drugs. BMJ 1969; 1: 536–9PubMedCrossRef
3.
Zurück zum Zitat Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. JAMA 1998; 279: 1200–7PubMedCrossRef Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. JAMA 1998; 279: 1200–7PubMedCrossRef
5.
Zurück zum Zitat Classen DC, Burke JP, Pestotnik SL, et al. Surveillance for quality assessment: IV. surveillance using a hospital information system. Infect Control Hosp Epidemiol 1991; 12: 239–44PubMedCrossRef Classen DC, Burke JP, Pestotnik SL, et al. Surveillance for quality assessment: IV. surveillance using a hospital information system. Infect Control Hosp Epidemiol 1991; 12: 239–44PubMedCrossRef
6.
Zurück zum Zitat Muehlberger N, Schneeweiss S, Hasford J. Adverse drug reaction monitoring — cost and benefit considerations part I: frequency of adverse drug reactions causing hospital admission. Pharmacoepidemiol Drug Saf 1997; 6(3 Suppl.): S71–7PubMedCrossRef Muehlberger N, Schneeweiss S, Hasford J. Adverse drug reaction monitoring — cost and benefit considerations part I: frequency of adverse drug reactions causing hospital admission. Pharmacoepidemiol Drug Saf 1997; 6(3 Suppl.): S71–7PubMedCrossRef
7.
Zurück zum Zitat Goettler M, Schneeweiss S, Hasford J. Adverse drug reaction monitoring — cost and benefit considerations part II: cost and preventability of adverse drug reactions leading to hospital admission. Pharmacoepidemiol Drug Saf 1997; 6(3 Suppl.): S79–90PubMedCrossRef Goettler M, Schneeweiss S, Hasford J. Adverse drug reaction monitoring — cost and benefit considerations part II: cost and preventability of adverse drug reactions leading to hospital admission. Pharmacoepidemiol Drug Saf 1997; 6(3 Suppl.): S79–90PubMedCrossRef
8.
Zurück zum Zitat Hallas J, Gram LF, Grodum E, et al. Drug related admissions to medical wards: a population based survey. Br J Clin Pharmacol 1992; 33: 61–8PubMedCrossRef Hallas J, Gram LF, Grodum E, et al. Drug related admissions to medical wards: a population based survey. Br J Clin Pharmacol 1992; 33: 61–8PubMedCrossRef
9.
Zurück zum Zitat Schneeweiss S, Göttler M, Hasford J, et al. First results from an intensified monitoring system to estimate drug-related hospital admissions. Br J Clin Pharmacol. Br J Clin Pharmacol 2001; 52: 196–200 Schneeweiss S, Göttler M, Hasford J, et al. First results from an intensified monitoring system to estimate drug-related hospital admissions. Br J Clin Pharmacol. Br J Clin Pharmacol 2001; 52: 196–200
10.
Zurück zum Zitat Evans JMM, MacDonald TM. Record-linkage for pharmacovigilance in Scotland. Br J Clin Pharmacol 1999; 47: 105–10PubMedCrossRef Evans JMM, MacDonald TM. Record-linkage for pharmacovigilance in Scotland. Br J Clin Pharmacol 1999; 47: 105–10PubMedCrossRef
11.
Zurück zum Zitat Currie CJ, MacDonald TM. Use of routine healthcare data in safe and cost-effective drug use. Drug Saf 2000; 22: 97–102PubMedCrossRef Currie CJ, MacDonald TM. Use of routine healthcare data in safe and cost-effective drug use. Drug Saf 2000; 22: 97–102PubMedCrossRef
12.
Zurück zum Zitat Teweleit S, Kuschel U, Hippius M, et al. Manifestation und Präventionsmöglichkeiten unerwünschter Arzneimittelwirkungen (UAW) in der Pharmakotherapie von Herz-Kreislauferkrankungen. Med Klin 2001; 96: 442–50CrossRef Teweleit S, Kuschel U, Hippius M, et al. Manifestation und Präventionsmöglichkeiten unerwünschter Arzneimittelwirkungen (UAW) in der Pharmakotherapie von Herz-Kreislauferkrankungen. Med Klin 2001; 96: 442–50CrossRef
13.
Zurück zum Zitat Hayes JL, Evans JMM, Lipworth BP, et al. Potentially hazardous co-prescribing of β-adrenoceptor antagonists and agonists in the community. Br J Gen Pract 1996; 46: 423–5PubMed Hayes JL, Evans JMM, Lipworth BP, et al. Potentially hazardous co-prescribing of β-adrenoceptor antagonists and agonists in the community. Br J Gen Pract 1996; 46: 423–5PubMed
14.
Zurück zum Zitat Bates DW, Spell N, Cullen DC, et al. The costs of adverse drug events in hospitalized patients. JAMA 1997; 277: 307–11PubMedCrossRef Bates DW, Spell N, Cullen DC, et al. The costs of adverse drug events in hospitalized patients. JAMA 1997; 277: 307–11PubMedCrossRef
15.
Zurück zum Zitat Classen DC, Pestotnik SL, Evans RS, et al. Adverse drug events in hospitalized patients. JAMA 1997; 277: 301–6PubMedCrossRef Classen DC, Pestotnik SL, Evans RS, et al. Adverse drug events in hospitalized patients. JAMA 1997; 277: 301–6PubMedCrossRef
16.
Zurück zum Zitat van den Bemt PMLA, Egberts ACG, Lenderink AW, et al. Adverse drug events in hospitalised patients: a comparison of doctors, nurses and patients as sources of reports. Eur J Clin Pharmacol 1999; 55: 155–8PubMedCrossRef van den Bemt PMLA, Egberts ACG, Lenderink AW, et al. Adverse drug events in hospitalised patients: a comparison of doctors, nurses and patients as sources of reports. Eur J Clin Pharmacol 1999; 55: 155–8PubMedCrossRef
17.
Zurück zum Zitat Mannesse CK, Derkx FHM, de Ridder MAJ, et al. Adverse drug reactions in elderly patients as contributing factor for hospital admission: cross sectional study. BMJ 1997; 315: 1057–9PubMedCrossRef Mannesse CK, Derkx FHM, de Ridder MAJ, et al. Adverse drug reactions in elderly patients as contributing factor for hospital admission: cross sectional study. BMJ 1997; 315: 1057–9PubMedCrossRef
18.
Zurück zum Zitat Moore N, Lecointre D, Noblet C, et al. Frequency and cost of serious adverse drug reactions in a department of general medicine.Br J Clin Pharmacol 1998; 45: 301–8PubMedCrossRef Moore N, Lecointre D, Noblet C, et al. Frequency and cost of serious adverse drug reactions in a department of general medicine.Br J Clin Pharmacol 1998; 45: 301–8PubMedCrossRef
19.
Zurück zum Zitat Martinez-Mir I, Garcia-Lopez M, Palop V, et al. A prospective study of adverse drug reactions as a cause of admission to a pediatric hospital. Br J Clin Pharmacol 1996; 42: 319–24PubMedCrossRef Martinez-Mir I, Garcia-Lopez M, Palop V, et al. A prospective study of adverse drug reactions as a cause of admission to a pediatric hospital. Br J Clin Pharmacol 1996; 42: 319–24PubMedCrossRef
20.
Zurück zum Zitat Francis GS. Cardiac complications in the intensive care unit. Clin Chest Med 1999; 20: 269–85PubMedCrossRef Francis GS. Cardiac complications in the intensive care unit. Clin Chest Med 1999; 20: 269–85PubMedCrossRef
21.
Zurück zum Zitat Classen DC, Pestotnik SL, Evans RS, et al. Computerized surveillance of adverse drug events in hospital patients. JAMA 1991; 266: 2847–51PubMedCrossRef Classen DC, Pestotnik SL, Evans RS, et al. Computerized surveillance of adverse drug events in hospital patients. JAMA 1991; 266: 2847–51PubMedCrossRef
22.
Zurück zum Zitat Leape LL, Bates DW, Cullen DC, et al. System analysis of adverse drug events. JAMA 1995; 274: 35–43PubMedCrossRef Leape LL, Bates DW, Cullen DC, et al. System analysis of adverse drug events. JAMA 1995; 274: 35–43PubMedCrossRef
23.
Zurück zum Zitat Dormann H, Muth-Selbach U, Krebs S, et al. Incidence and costs of adverse drug reactions during hospitalisation. Drug Saf 2000; 2: 161–8CrossRef Dormann H, Muth-Selbach U, Krebs S, et al. Incidence and costs of adverse drug reactions during hospitalisation. Drug Saf 2000; 2: 161–8CrossRef
24.
Zurück zum Zitat Azaz-Livshits T, Levy M, Sadan B, et al. Computerized surveillance of adverse drug reactions in hospital: pilot study. Br J Clin Pharmacol 1998; 45: 309–14PubMedCrossRef Azaz-Livshits T, Levy M, Sadan B, et al. Computerized surveillance of adverse drug reactions in hospital: pilot study. Br J Clin Pharmacol 1998; 45: 309–14PubMedCrossRef
25.
Zurück zum Zitat Leape L, Brennan T, Laird N, et al. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med 1991; 324: 377–84PubMedCrossRef Leape L, Brennan T, Laird N, et al. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med 1991; 324: 377–84PubMedCrossRef
26.
Zurück zum Zitat Tegeder I, Levy M, Muth-Selbach U, et al. Retrospective analysis of the frequency and recognition of adverse drug reactions by means of automatically recorded laboratory signals. Br J Clin Pharmacol 1999; 47: 557–64PubMedCrossRef Tegeder I, Levy M, Muth-Selbach U, et al. Retrospective analysis of the frequency and recognition of adverse drug reactions by means of automatically recorded laboratory signals. Br J Clin Pharmacol 1999; 47: 557–64PubMedCrossRef
27.
Zurück zum Zitat Lau HS, Florax C, Porsius AJ, et al. The completeness of medication histories in hospital medical records of patients admitted to general internal medicine wards. Br J Clin Pharmacol 2000; 49: 597–603PubMedCrossRef Lau HS, Florax C, Porsius AJ, et al. The completeness of medication histories in hospital medical records of patients admitted to general internal medicine wards. Br J Clin Pharmacol 2000; 49: 597–603PubMedCrossRef
28.
Zurück zum Zitat Bowman L, Carlstedt BC, Black CD. Incidence of adverse drug reactions in adult medical inpatients. Can J Hosp Pharm 1994; 47: 209–16PubMed Bowman L, Carlstedt BC, Black CD. Incidence of adverse drug reactions in adult medical inpatients. Can J Hosp Pharm 1994; 47: 209–16PubMed
29.
Zurück zum Zitat Leape LL, Cullen DJ, Clapp MD, et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA 1999; 282: 267–70PubMedCrossRef Leape LL, Cullen DJ, Clapp MD, et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA 1999; 282: 267–70PubMedCrossRef
30.
Zurück zum Zitat Roughead EE, Gilbert AL, Primrose JG, et al. Drug-related hospital admissions: a review of Australian studies published 1988 — 1996. Med J Aust 1998; 168: 405–8PubMed Roughead EE, Gilbert AL, Primrose JG, et al. Drug-related hospital admissions: a review of Australian studies published 1988 — 1996. Med J Aust 1998; 168: 405–8PubMed
31.
Zurück zum Zitat Beard K. Adverse drug reactions as a cause of hospital admission in the aged. Drugs Aging 1992; 2: 356–67PubMedCrossRef Beard K. Adverse drug reactions as a cause of hospital admission in the aged. Drugs Aging 1992; 2: 356–67PubMedCrossRef
32.
Zurück zum Zitat Fattinger K, Roos M, Vergères P, et al. Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine. Br J Clin Pharmacol 2000; 49: 158–67PubMedCrossRef Fattinger K, Roos M, Vergères P, et al. Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine. Br J Clin Pharmacol 2000; 49: 158–67PubMedCrossRef
33.
Zurück zum Zitat Thürmann PA, Hompesch BC. Influence of gender on pharmacokinetics and pharmacodynamics of drugs. Int J Clin Pharmacol Ther 1998; 36: 586–90PubMed Thürmann PA, Hompesch BC. Influence of gender on pharmacokinetics and pharmacodynamics of drugs. Int J Clin Pharmacol Ther 1998; 36: 586–90PubMed
34.
Zurück zum Zitat Imbs JL, Pouyanne P, Haramburu F, et al. Iatrogénie médicamenteuse: estimation de sa prévalence dans les hôpitaux publics français. Thérapie 1999; 54: 21–7PubMed Imbs JL, Pouyanne P, Haramburu F, et al. Iatrogénie médicamenteuse: estimation de sa prévalence dans les hôpitaux publics français. Thérapie 1999; 54: 21–7PubMed
35.
Zurück zum Zitat Pouyanne P, Haramburu F, Imbs JL, et al., for the French Pharmacovigilance Centres. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. BMJ 2000; 320: 1036PubMedCrossRef Pouyanne P, Haramburu F, Imbs JL, et al., for the French Pharmacovigilance Centres. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. BMJ 2000; 320: 1036PubMedCrossRef
36.
37.
Zurück zum Zitat Schmitt K, Windecker R, Steffen J, et al. Detection of adverse drug reactions by a computer-based generation of laboratory signals [abstract]. Br J Clin Pharmacol 2000 [Abstracts of CPT 2000]; 87: A331 Schmitt K, Windecker R, Steffen J, et al. Detection of adverse drug reactions by a computer-based generation of laboratory signals [abstract]. Br J Clin Pharmacol 2000 [Abstracts of CPT 2000]; 87: A331
38.
Zurück zum Zitat World Health Organization. International drug monitoring: the role of the hospital. WHO Tech Rep Ser 1969; No. 425 World Health Organization. International drug monitoring: the role of the hospital. WHO Tech Rep Ser 1969; No. 425
39.
Zurück zum Zitat Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255–9PubMedCrossRef Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255–9PubMedCrossRef
40.
Zurück zum Zitat Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. JAMA 1995; 274: 29–34PubMedCrossRef Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. JAMA 1995; 274: 29–34PubMedCrossRef
41.
Zurück zum Zitat Bergman U, Wiholm BE. Drug-related problems causing admission to a medical clinic. Eur J Clin Pharmacol 1981; 20: 193–200PubMedCrossRef Bergman U, Wiholm BE. Drug-related problems causing admission to a medical clinic. Eur J Clin Pharmacol 1981; 20: 193–200PubMedCrossRef
42.
43.
Zurück zum Zitat Pirmohamed M, Breckenridge AM, Kitteringham NR, et al. Adverse drug reactions. BMJ 1998; 316: 1295-8 Pirmohamed M, Breckenridge AM, Kitteringham NR, et al. Adverse drug reactions. BMJ 1998; 316: 1295-8
44.
Zurück zum Zitat Naranjo S, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239–45PubMedCrossRef Naranjo S, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239–45PubMedCrossRef
45.
Zurück zum Zitat Netting an important database [editorial]. Lancet 2001; 357: 649 Netting an important database [editorial]. Lancet 2001; 357: 649
46.
Zurück zum Zitat Hallas J, Harvald B, Worm J, et al. Drug related hospital admissions. Eur J Clin Pharmacol 1993; 45: 199–203PubMedCrossRef Hallas J, Harvald B, Worm J, et al. Drug related hospital admissions. Eur J Clin Pharmacol 1993; 45: 199–203PubMedCrossRef
47.
Zurück zum Zitat Evans RS, Pestotnik SL, Classen DC, et al. Preventing adverse drug events in hospitalized patients. Ann Pharmacother 1994; 28: 523–7PubMed Evans RS, Pestotnik SL, Classen DC, et al. Preventing adverse drug events in hospitalized patients. Ann Pharmacother 1994; 28: 523–7PubMed
48.
Zurück zum Zitat Landis NT. ADE rate uncertain, reporting systems inadequate, GAO tells legislators. Am J Health Syst Pharm 2000; 57:515–23PubMed Landis NT. ADE rate uncertain, reporting systems inadequate, GAO tells legislators. Am J Health Syst Pharm 2000; 57:515–23PubMed
49.
Zurück zum Zitat Wood AJ. Thrombotic thrombocytopenic purpura and clopidogrel — a need for new approaches to drug safety. N Engl J Med 2000; 342: 1824–6PubMedCrossRef Wood AJ. Thrombotic thrombocytopenic purpura and clopidogrel — a need for new approaches to drug safety. N Engl J Med 2000; 342: 1824–6PubMedCrossRef
50.
Zurück zum Zitat Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000; 342: 1773–7PubMedCrossRef Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000; 342: 1773–7PubMedCrossRef
51.
Zurück zum Zitat Moore N. The role of the clinical pharmacologist in the management of adverse drug reactions. Drug Saf 2001; 24: 1–7PubMedCrossRef Moore N. The role of the clinical pharmacologist in the management of adverse drug reactions. Drug Saf 2001; 24: 1–7PubMedCrossRef
Metadaten
Titel
Methods and Systems to Detect Adverse Drug Reactions in Hospitals
verfasst von
Dr Petra A. Thürmann
Publikationsdatum
01.11.2001
Verlag
Springer International Publishing
Erschienen in
Drug Safety / Ausgabe 13/2001
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200124130-00003

Weitere Artikel der Ausgabe 13/2001

Drug Safety 13/2001 Zur Ausgabe